1. Zuranolone for the treatment of postpartum depression,2024
2. Barnes, K. N., Vogl, C. M., & Nelson, L. A. (2023). Zuranolone: The first FDA-approved oral treatment option for postpartum depression. Annals of Pharmacotherapy. Advance online publication. https://doi.org/10.1177/10600280231204953
3. Clinically relevant drug interactions in HSCT;Bauters,2019
4. ZURZUVAE™ (zuranolone) CIV, a landmark oral treatment for women with postpartum depression (PPD), is now available in the U.S.,2023
5. Zuranolone in major depressive disorder: Results from MOUNTAIN—A phase 3, multicenter, double-blind, randomized, placebo-controlled trial;Clayton;Journal of Clinical Psychiatry,2023